FACTS ABOUT TRASTUZUMAB DERUXTECAN REVEALED

In July 2024, the CHMP adopted a constructive viewpoint, recommending the granting of a advertising and marketing authorization for the medicinal product or service Tuznue, supposed for your procedure of breast and gastric cancer.Trastuzumab works by binding to HER2, a protein located in large levels on some cancer cells and leads to them to grow.N